다약제 치료를 받는 조현병 환자에서 Aripiprazole Once-Monthly 투여의 임상적 부담

• Published in: Journal of the Korean Society of Biological Psychiatry pp. 34 - 39
• Main Authors: 문지완, 신영철, 조성준, 양혜련, 정슬아, 정수봉, 장진구, 김원형, 이상민, 김장래, 방민지, 김민경, 김은수, 신동원, 오강섭, 전상원, 김준형
• Format: Journal Article
• Language: Korean
• Published: 대한생물정신의학회 01.10.2024
• Subjects: 정신과학
• ISSN: 1225-8709; 1225-8709
• DOI: 10.22857/kjbp.2024.31.2.003

Objectives This study aimed to assess the clinical burden, a critical determinant of medication adherence in patients with schizophrenia, after the administration of Aripiprazole once-monthly (AOM). Methods This study was a retrospective, non-interventional, multicenter, naturalistic observational study conducted through the analysis of participants’ electronic medical records. Study participants were recruited from eight sites. Data were collected at baseline, defined as the time of AOM administration, and at 1, 3, 6, 9, and 12 months thereafter. The primary outcome measure was the change in the Clinical Global Impression-Clinical Benefit (CGI-CB) score over 12 months, and the secondary outcome measure was the change in the Clinical Global Impression-Improvement (CGI-I) score. Results The data of 139 participants were analyzed, revealing a statistically significant decrease of 26.8% in CGI-CB scores and 13.4% in CGI-I scores over 12 months. Upon comparison between adjacent visit intervals, significant reductions were observed for both measures between month 3 and month 6. Conclusions This study is the first multicenter investigation to simultaneously evaluate the clinical efficacy and tolerability of transitioning to AOM in the context of polypharmacy. The study suggested that AOM may contribute to reducing the clinical burden, thereby improving the quality of life for patients with schizophrenia. KCI Citation Count: 0